Transgenic mice overexpressing FGF21 in the liver are protected against diet-induced obesity [10], and FGF21 pharmacotherapy in diabetic and obese mice rapidly improves metabolic abnormalities [15, 16]. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.